详情页 - 四川省肿瘤医院知识库

当前位置：首页 > 详情页

Afatinib as a Potential Therapeutic Option for Non-small Cell Lung Cancer Patients with EGFR G724S

文献详情

资源类型：

WOS体系：

收录情况： ◇ SCIE

作者：

机构： [1]Department of Clinical Research, Sun Yat-Sen University Cancer Center, Guangzhou/CN [2]Department of Medical Oncology, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China,Chengdu/CN [3]Nantong Hospital of Traditional Chinese Medicine, Nantong Hospital To Nanjing University of Chinese Medicine, Nantong/ CN [4]Cancer Center, Guangdong General Hospital, Guangzhou/CN [5]Burning Rock Biotech, Guangzhou/CN

出处：

ISSN：

关键词： Afatinib EGFR G724S non-small cell lung cancer

语种：

WOS：

中科院(CAS)分区：

出版当年[2021]版：

大类 | 1 区

医学

小类 | 1 区肿瘤学 1 区呼吸系统

最新[2023]版：

大类 | 1 区

医学

小类 | 1 区肿瘤学 1 区呼吸系统

JCR分区：

出版当年[2021]版：

Q1 ONCOLOGY Q1 RESPIRATORY SYSTEM

最新[2023]版：

Q1 ONCOLOGY Q1 RESPIRATORY SYSTEM

影响因子： 21.1 最新[2023版] 16.5 最新五年平均 20.121 出版当年[2021版] 16.919 出版当年五年平均 15.609 出版前一年[2020版] 20.4 出版后一年[2022版]

第一作者：

第一作者机构： [1]Department of Clinical Research, Sun Yat-Sen University Cancer Center, Guangzhou/CN

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]Afatinib as a Potential Therapeutic Option for Patients With NSCLC With EGFR G724S. [2]ERBB2-Mutated Metastatic Non-Small Cell Lung Cancer: Response and Resistance to Targeted Therapies [3]Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial [4]Therapeutic Efficacy Comparison of 5 Major EGFR-TKIs in Advanced EGFR-positive Non-Small-cell Lung Cancer: A Network Meta-analysis Based on Head-to-Head Trials [5]Rare EGFR E709-T710delinsX: Molecular characteristics and superior response to afatinib treatment in NSCLC patients [6]Neoadjuvant and Adjuvant Therapy for Non-Small Cell Lung Cancer [7]KRASG12C Inhibitors in Non-Small Cell Lung Cancer: A Review [8]阿法替尼治疗晚期非小细胞肺癌临床疗效和安全性的Meta分析 [9]Repotrectinib in ROS1 Fusion-Positive Non-Small-Cell Lung Cancer [10]Afatinib versus gemcitabine/cisplatin for first-line treatment of Chinese patients with advanced non-small-cell lung cancer harboring EGFR mutations: subgroup analysis of the LUX-Lung 6 trial.